Denali Therapeutics Inc. (DNLI) Financials

DNLI Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.2 billion 322.8 million
March 31, 2026 1.3 billion 339.9 million
Dec. 31, 2025 1.1 billion 131.1 million
Sept. 30, 2025 1.1 billion 129.4 million

DNLI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -97.8 million 22.9 million
March 31, 2026 -133.7 million 23.1 million
Dec. 31, 2025 -100.1 million 24.0 million
Sept. 30, 2025 -105.9 million 25.1 million

DNLI Net Income

No data available :(

DNLI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 710.5 million - 27.5 million
March 31, 2026 987.7 million - 30.2 million
Dec. 31, 2025 867.9 million - 36.8 million
Sept. 30, 2025 848.2 million - 35.2 million

DNLI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 187.3 million
March 31, 2026 186.6 million
Dec. 31, 2025 175.5 million
Sept. 30, 2025 172.4 million

DNLI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 805000 97.0 million 36.3 million -
March 31, 2026 2.5 million 103.8 million 30.7 million -
Dec. 31, 2025 1.5 million 97.9 million 36.6 million -
Sept. 30, 2025 1.4 million 102.0 million 35.5 million -

DNLI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 3.6 million 93000
March 31, 2026 - 2.8 million
Dec. 31, 2025 - 2.9 million
Sept. 30, 2025 - 102.0 million

DNLI Revenue by Segment
Graph available only for paid members. Upgrade to see it.

DNLI

Price: $24.40

52 week price:
12.58
27.30

Earnings Per Share: -2.84 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 517900

Market Capitalization: 4.0 billion

Links: